Nancy E Davidson

Nancy E Davidson

UNVERIFIED PROFILE

Are you Nancy E Davidson?   Register this Author

Register author
Nancy E Davidson

Nancy E Davidson

Publications by authors named "Nancy E Davidson"

Are you Nancy E Davidson?   Register this Author

100Publications

3885Reads

32Profile Views

Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?

Oncology (Williston Park) 2019 06;33(6):243-6

View Article

Download full-text PDF

Source
June 2019

Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?

J Natl Cancer Inst 2019 02;111(2):107-108

Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376902PMC
February 2019

Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.

J Natl Cancer Inst 2019 Jan 28. Epub 2019 Jan 28.

Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624165PMC
January 2019

Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.

Cancer Res 2018 11 18;78(21):6209-6222. Epub 2018 Sep 18.

Women's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Magee-Womens Research Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-1416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507416PMC
November 2018

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.

Sci Rep 2018 11 23;8(1):17313. Epub 2018 Nov 23.

Women's Cancer Research Center, Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, Magee Womens Research Institute, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35470-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251935PMC
November 2018

HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.

Int J Cancer 2018 09 20;143(6):1388-1401. Epub 2018 Apr 20.

Women's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.31419
Publisher Site
http://dx.doi.org/10.1002/ijc.31419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105499PMC
September 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.

J Oncol Pract 2018 08 10;14(8):501-504. Epub 2018 Jul 10.

The University of Texas MD Anderson Cancer Center, Houston, TX; American Society of Clinical Oncology, Alexandria, VA; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00290DOI Listing
August 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background.

Authors:
Nancy E Davidson

JAMA Oncol 2018 06;4(6):836-837

Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.4167DOI Listing
June 2018

Searching for the IDEAL Duration of Adjuvant Endocrine Therapy.

J Natl Cancer Inst 2018 01;110(1)

Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx143DOI Listing
January 2018

Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?

Nat Rev Clin Oncol 2017 12 8;14(12):715-716. Epub 2017 Aug 8.

Fred Hutchinson Cancer Research Center and University of Washington, 1100 Fairview Avenue North, Thomas Building Room D5-310, Seattle, Washington 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.125DOI Listing
December 2017

Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.

Oncotarget 2017 Oct 19;8(47):81737-81753. Epub 2017 Jul 19.

Women's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669845PMC
October 2017

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

JAMA Oncol 2017 May;3(5):666-671

Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania2Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania7Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.5630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508875PMC
May 2017

Practical Approach to Triple-Negative Breast Cancer.

J Oncol Pract 2017 05;13(5):293-300

University of Washington, Fred Hutchinson Cancer Research Center, and Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.022632DOI Listing
May 2017

Optimal duration of trastuzumab for early HER2-positive breast cancer.

Lancet 2017 03 20;389(10075):1167-1168. Epub 2017 Feb 20.

Department of Medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)30322-7DOI Listing
March 2017

Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.

Am Soc Clin Oncol Educ Book 2016 ;35:23-32

From the Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Department of Oncology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159069DOI Listing
January 2017

Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.

Clin Cancer Res 2016 Nov 16;22(21):5362-5369. Epub 2016 May 16.

Women's Cancer Research Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, Magee Womens Research Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093028PMC
November 2016

Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new.

J Thorac Dis 2016 Nov;8(11):2971-2974

University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.11.18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179425PMC
November 2016

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?

Clin Cancer Res 2016 Oct 12;22(20):4963-4965. Epub 2016 Aug 12.

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/22/20/4963.ful
Web Search
http://dx.doi.org/10.1158/1078-0432.CCR-16-1513DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154749PMC
October 2016

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

J Clin Oncol 2016 08 31;34(24):2925-34. Epub 2016 May 31.

Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Harvard Medical School; Therese Mulvey and Jeffrey Peppercorn, Massachusetts General Hospital; Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh; Adam P. Dicker, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA; Dana S. Wollins and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Douglas W. Blayney, Stanford University Medical Center, Stanford; Patricia A. Ganz, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles; Peter P. Yu, Palo Alto Medical Foundation, Palo Alto, CA; J. Russell Hoverman, Texas Oncology, Dallas, TX; Robert Langdon, Nebraska Cancer Specialists; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Neal J. Meropol, University Hospitals Case Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, and Case Western Reserve University, Cleveland, OH; Lee Newcomer, UnitedHealthcare, Minneapolis, MN; Blase Polite, University of Chicago Medicine, Chicago, IL; Derek Raghavan, Levine Cancer Institute, Charlotte, NC; Gregory Rossi, AstraZeneca, Macclesfield, United Kingdom; Leonard Saltz and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Thomas J. Smith, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2518DOI Listing
August 2016

Breast cancer: The 21-gene recurrence score - biology remains at the forefront.

Nat Rev Clin Oncol 2016 08 14;13(8):470-2. Epub 2016 Jun 14.

Department of Medicine, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, Pennsylvania 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.98DOI Listing
August 2016

"Take two"? The role of second opinions for breast biopsy specimens.

BMJ 2016 06 23;353:i3256. Epub 2016 Jun 23.

Departments of Pathology and Medicine, University of Pittsburgh and Magee Women's Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.i3256DOI Listing
June 2016

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

J Clin Oncol 2016 05 4;34(14):1580-3. Epub 2016 Jan 4.

University of Pittsburgh Cancer Institute and UPMC CancerCenter, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.3728DOI Listing
May 2016

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

J Clin Oncol 2016 05 16;34(14):1689-701. Epub 2016 Feb 16.

Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9573DOI Listing
May 2016

Reply to C. Shah et al.

J Clin Oncol 2016 05 21;34(15):1824-5. Epub 2016 Mar 21.

University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4714DOI Listing
May 2016

Serendipity and purpose.

Authors:
Nancy E Davidson

Endocr Relat Cancer 2016 05 8;23(5):P1-3. Epub 2016 Apr 8.

University of PittsburghCancer Institute, Pittsburgh, Pennsylvania, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-16-0149DOI Listing
May 2016

Conquering Metastatic Breast Cancer.

Authors:
Nancy E Davidson

J Oncol Pract 2016 Jan;12(1):11-2

University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.009167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960463PMC
January 2016

A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.

Horm Cancer 2015 Dec 26;6(5-6):214-24. Epub 2015 Jun 26.

Department of Pharmacology and Chemical Biology, Women's Cancer Research Center (WCRC), Magee-Womens Research Institute (MWRI), University of Pittsburgh Cancer Institute (UPCI), 204 Craft Avenue, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-015-0230-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807402PMC
December 2015

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Br J Cancer 2015 Dec 1;113(12):1651-7. Epub 2015 Dec 1.

Department of Medicine, University of Pittsburgh Cancer Institute and UMPC Cancer Center, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701997PMC
December 2015

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Breast 2015 Nov;24 Suppl 2:S120-5

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute and UPMC CancerCenter, University of Pittsburgh, 5150 Centre Avenue, Suite 500, Pittsburgh, PA 15232, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776150016
Publisher Site
http://dx.doi.org/10.1016/j.breast.2015.07.027DOI Listing
November 2015

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

J Clin Oncol 2015 Nov 14;33(33):3938-44. Epub 2015 Sep 14.

Lawrence J. Solin, Albert Einstein Healthcare Network, Philadelphia; Nancy E. Davidson, University of Pittsburgh, Pittsburgh, PA; Robert Gray, Dana-Farber Cancer Institute; Abram Recht, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; Mary Ann Lowen, Baystate Medical Center, Springfield, MA; Lorie L. Hughes, Harris Radiation Therapy Center at Gordon Hospital, Calhoun; William C. Wood, Emory University, Atlanta, GA; Sunil S. Badve, Indiana University, Indianapolis, IN; Frederick L. Baehner, University of California, San Francisco, San Francisco, CA; James N. Ingle, Mayo Clinic, Rochester, MN; Edith A. Perez, Mayo Clinic, Jacksonville, FL; and Joseph A. Sparano, Montefiore Medical Center, Bronx, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652014PMC
November 2015

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Breast Cancer Res Treat 2015 Sep 18;153(2):311-21. Epub 2015 Aug 18.

Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, 300 Halket Street, Suite 2601, Pittsburgh, PA, 15217, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3551-8DOI Listing
September 2015

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

J Clin Oncol 2015 Aug 22;33(23):2563-77. Epub 2015 Jun 22.

Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Harvard Medical School; Jeffrey Peppercorn, Massachusetts General Hospital; Deborah Schrag, Dana-Farber Cancer Institute, Boston; Therese Mulvey, Southcoast Centers for Cancer Care, Fall River, MA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh; Adam P. Dicker, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA; Dana S. Wollins, Courtney Tyne, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Douglas W. Blayney, Stanford University Medical Center, Stanford; Patricia A. Ganz, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles; Peter P. Yu, Palo Alto Medical Foundation, Palo Alto, CA; Diane Blum, National Executive Service Corps; Leonard Saltz and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; J. Russell Hoverman, Texas Oncology, Dallas, TX; Robert Langdon, Nebraska Cancer Specialists, Omaha, NE; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Neal J. Meropol, University Hospitals Case Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Lee Newcomer, UnitedHealthcare, Minneapolis, MN; Blase Polite, University of Chicago Medicine, Chicago, IL; Derek Raghavan, Levine Cancer Institute, Charlotte, NC; Gregory Rossi, AstraZeneca, Macclesfield, Cheshire, United Kingdom; and Thomas J. Smith, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.61.6706
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.6706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427PMC
August 2015

MCF-7 cells--changing the course of breast cancer research and care for 45 years.

J Natl Cancer Inst 2015 Jul 31;107(7). Epub 2015 Mar 31.

Departments of Pharmacology and Chemical Biology, Human Genetics, and Medicine, Women's Cancer Research Center, Magee-Womens Research Institute, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (AVL, SO, NED); University of Pittsburgh Cancer Institute and UPMC Cancer Center, 5150 Center Avenue, Pittsburgh, PA (NED).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djv073DOI Listing
July 2015

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

J Clin Oncol 2015 Jul 15;33(21):2353-60. Epub 2015 Jun 15.

Joseph A. Sparano, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; Fengmin Zhao and Jennifer A. Ligibel, Dana-Farber Cancer Institute-Harvard University, Boston, MA; Silvana Martino, John Wayne Cancer Institute, Santa Monica, CA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Tom Saphner, Vince Lombardi Cancer Center, Two Rivers, WI; Antonio C. Wolff, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; George W. Sledge Jr, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; William C. Wood, Winship Cancer Center, Emory University, Atlanta, GA; and Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/21/2353.full.pdf
Web Search
http://jco.ascopubs.org/content/early/2015/06/15/JCO.2015.60
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.60.9271
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.60.9271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829PMC
July 2015

Can circulating tumor cells predict resistance in metastatic breast cancer?

Clin Cancer Res 2015 Jun 2;21(11):2421-3. Epub 2015 Feb 2.

Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute and UPMC CancerCenter, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2967DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694574PMC
June 2015

Expertise vs evidence in assessment of breast biopsies: an atypical science.

JAMA 2015 Mar;313(11):1109-10

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.1945DOI Listing
March 2015

Should we embrace or ablate our urge to (ovarian) suppress?

J Clin Oncol 2014 Dec 3;32(35):3920-2. Epub 2014 Nov 3.

University of Pittsburgh Cancer Institute; University of Pittsburgh Medical Center CancerCenter; and University of Pittsburgh Medical Center Magee-Womens Breast Cancer Program, Pittsburgh, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9953DOI Listing
December 2014

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

J Clin Oncol 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20.

Edith A. Perez, Gerardo Colon-Otero, the Mayo Clinic, Jacksonville; Eleftherios Mamounas, University of Florida Health Cancer Center-Orlando Health, Orlando, FL; Edward H. Romond, University of Kentucky, Lexington, KY; Vera J. Suman, Mayo Clinic, Rochester, MN; Jong-Hyeon Jeong, Priya Rastogi, University of Pittsburgh; Nancy E. Davidson, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny General Hospital, Pittsburgh, PA; George Sledge, Stanford University School of Medicine, Stanford; Silvana Martino, The Angeles Clinic and Research Institute, Santa Monica, CA; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jo Anne Zujewski, National Institutes of Health, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.5730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805PMC
November 2014

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Cancer Immunol Res 2014 Oct 12;2(10):949-61. Epub 2014 Aug 12.

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Program in Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211036PMC
October 2014

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2014 Oct 2;32(29):3307-29. Epub 2014 Sep 2.

Ann H. Partridge, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center; Beverly Moy, Massachusetts General Hospital, Boston, MA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Norfolk, VA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Nancy E. Davidson, University of Pittsburgh Cancer Institute/University of Pittsburgh Medical Center, Pittsburgh, PA; Angelo Di Leo, Sandro Pitigliani Medical Oncology Unit, Prato, Italy; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Douglas Yee, University of Minnesota/Masonic Cancer Center, Minneapolis, MN; Shelley B. Brundage, Patient Representative, Washington, DC; Maggie Wilcox, Independent Cancer Patients' Voice; and Ian E. Smith, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.7479
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.7479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042PMC
October 2014

Epigenetic reprogramming in breast cancer: from new targets to new therapies.

Ann Med 2014 Sep 24;46(6):397-408. Epub 2014 Jul 24.

Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, The Women's Cancer Research Center , Pittsburgh, PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07853890.2014.923740DOI Listing
September 2014

Integrated proteomic and metabolic analysis of breast cancer progression.

PLoS One 2013 27;8(9):e76220. Epub 2013 Sep 27.

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America ; Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076220PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785415PMC
July 2014

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2078-99. Epub 2014 May 5.

Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Ian Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Edith A. Perez, Mayo Clinic, Jacksonville; Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.0948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076031PMC
July 2014

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2100-8. Epub 2014 May 5.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Edith A. Perez, Mayo Clinic, Jacksonville; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian Krop, Eric P. Winter, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/19/2100.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0955
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366342PMC
July 2014

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

J Clin Oncol 2014 Jul 27;32(21):2255-69. Epub 2014 May 27.

Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester; Alexander J. Solky, Interlakes Onc and Hem PC, Rochester; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas A. Buchholz, Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston; Diana Rowden, Dallas, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Vered Stearns, Johns Hopkins School of Medicine, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876310PMC
July 2014

Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.

Breast Cancer Res Treat 2014 Jul 13;146(1):99-108. Epub 2014 Jun 13.

UPMC Cancer Research Pavilion, University of Pittsburgh Cancer Institute, Suite 500, 5150 Centre Ave, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3012-9DOI Listing
July 2014

Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Cell Mol Life Sci 2014 Apr;71(8):1549

Department of Cell Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00018-013-1376-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962223PMC
April 2014

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Cancer Res 2014 Mar 14;74(5):1463-74. Epub 2014 Jan 14.

Authors' Affiliations: Women's Cancer Research Center; Departments of Biomedical Informatics, Pharmacology and Chemical Biology, Biostatistics, Human Genetics, University of Pittsburgh; Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2779DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955299PMC
March 2014

Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration.

Nat Rev Clin Oncol 2014 Feb 14;11(2):71-2. Epub 2014 Jan 14.

University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, 5150 Center Avenue, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2013.250
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2013.250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677672PMC
February 2014

Obesity and breast cancer: a multipartite connection.

J Mammary Gland Biol Neoplasia 2013 Dec 5;18(3-4):253-5. Epub 2013 Nov 5.

Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1, Rm 145, Baltimore, MD, 21231, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10911-013-9306-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010071PMC
December 2013

The search for ESR1 mutations in breast cancer.

Nat Genet 2013 Dec;45(12):1415-6

Department of Pharmacology and Chemical Biology and Department of Medicine, University of Pittsburgh, Women's Cancer Research Center, University of Pittsburgh Cancer Institute and UPMC Cancer Center, and Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2831DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934882PMC
December 2013

Adjuvant endocrine therapy for breast cancer: how long is long enough?

Oncology (Williston Park) 2013 Dec;27(12):1210-6, 1224

View Article

Download full-text PDF

Source
December 2013

Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells.

Carcinogenesis 2013 Nov 10;34(11):2587-92. Epub 2013 Jul 10.

Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgt246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888356PMC
November 2013

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Clin Cancer Res 2013 Oct 21;19(20):5798-807. Epub 2013 Aug 21.

Authors' Affiliations: Section of Biostatistics; Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology; Division of Biomedical Statistics and Informatics and Medical Oncology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology and Hematology/Oncology, Mayo Clinic, Jacksonville, Florida; Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania; The Angeles Clinic and Research Institute, Santa Monica, California; Indiana University Medical Center Cancer Pavilion, Indianapolis, Indiana; Division of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa; Seattle Cancer Care Alliance, Seattle, Washington; and Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805021PMC
October 2013

Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer.

Cell Rep 2013 Sep;4(6):1061-2

Women's Cancer Research Center, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Magee-Womens Hospital and Magee-Womens Research Institute, Departments of Pharmacology and Chemical Biology and Medicine, University of Pittsburgh, Pittsburgh 15213, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2013.09.008DOI Listing
September 2013

Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.

Breast 2013 Aug;22 Suppl 2:S165-70

University of Pittsburgh Cancer Institute and UPMC Cancer Center, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.07.032DOI Listing
August 2013

Fifteen years of anti-HER2 therapy.

Authors:
Nancy E Davidson

Oncology (Williston Park) 2013 Mar;27(3):151

University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
March 2013

Treatment for breast cancer: is time really of the essence?

J Natl Cancer Inst 2013 Jan 21;105(2):80-2. Epub 2012 Dec 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs524DOI Listing
January 2013